Based on these findings, some orally available PARP inhibitors, such as olaparib, rucaparib, niraparib, and talazoparib, have been clinically used for treatment of BRCA-mutated cancers, including ovarian, breast, and prostate cancers (Table 6)8,178. This evidence concerns the gene PARP1 and cancer.